Organization
Adlai Nortye Biopharma
6 clinical trials
1 abstract
Clinical trial
Clinical Study Protocol AN4005X0101 An Open-Label, Multicenter, Phase 1 Study of AN4005 in Patients With Advanced TumorsStatus: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
An Open-Label Multicenter Phase Ib Study of AN0025 in Combination With Pembrolizumab in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-05-15
Clinical trial
An Open-Label Multicenter Phase Ib Study of AN0025 in Combination With Chemoradiotherapy in Patients With Locally Advanced/Locally Recurrent Esophageal CancerStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Multicenter, Single-Arm, Open-Label Phase I Clinical Study of Pelareorep With Paclitaxel in Advanced or Metastatic Breast CancerStatus: Completed, Estimated PCD: 2022-09-29
Clinical trial
An Open-Label, Multicenter, Phase 1a Study of AN2025 and AN0025 in Double Combination With Atezolizumab and in Triple Combination With Atezolizumab in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
The BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Abstract
Combinatorial immune biomarkers of efficacy on buparlisib and paclitaxel in patients with SCCHN: BERIL-1 sub-analysis.Org: Adlai Nortye USA Inc., Adlai Nortye Biopharma, Head and Neck Cancer Medical Oncology 3 Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Department of Oncology and Hemato-Oncology, University of Milan, and Division of Early Drug Development, European Institute of Oncology, IRCCS, Milan, Italy,